Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit

Fig. 1

Clinical and therapeutic features of case-index MDR A. baumannii bacteremia. Procalcitonin levels increased up to 7 mg/L under treatment with COL + RIF, which was expression of treatment failure. Rather, it started to decrease under COL + VAN + MEM therapy and reached the normal value after 15 days of such therapy. The decreasing levels of procalcitonin following therapy with COL + VAN + MEM was expression of treatment success. COL: Colistin, VAN: Vancomycin, RIF: Rifampin, MEM: Meropenem

Back to article page